TScan Therapeutics, Inc. WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell ...

TScan raises $30M through pre-funded warrants, extending its cash runway into Q1 2027, with a 37% premium over its last closing price. TScan stock gains in premarket trading following the ...

If you want to know who really controls TScan Therapeutics, Inc. (NASDAQ:TCRX), then you'll have to look at the makeup of its share registry. With 52% stake, institutions possess the maximum ...

TScan Therapeutics announces $30 million investment from Lynx1 Capital Management for pre-funded warrants, extending cash runway into early 2027. TScan Therapeutics, Inc. has announced a ...

TScan Therapeutics (TCRX) entered into a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of approximately $30M of pre-funded ...

TScan Therapeutics secures a $52.5 million term loan from Silicon Valley Bank to enhance financial flexibility and support cancer therapies. TScan Therapeutics, Inc. has announced a term loan ...

TScan Therapeutics has entered a new loan agreement with Silicon Valley Bank, securing up to $52.5 million to refinance existing debt and fund corporate purposes. This non-dilutive financing ...

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...